Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The District Consumer Disputes Redressal Commission-II, Chandigarh passed an Order in favour of the consumer for automatically levying a service charge and without obtaining the consent of the consumer; further, the opposite party refused to remove the said charge upon objection. The opposite party did not appear in the Consumer Court, hence, an ex-parte Order was passed. The opposite party was directed to refund ₹129 collected towards service charge and pay a lump-sum compensation of ₹5,000 towards harassment and litigation expenses within 45 days of receipt of the order.
Source: short-url.cc/1ymfE

2. India’s finance ministry has extended the customs duty exemption on imports of specified petrochemical products used in pharmaceutical manufacturing such as chemicals, plastics, textiles, packaging, and automotive manufacturing in view of the continuing global supply disruptions. The extension is intended to ensure the uninterrupted availability of essential raw materials, support domestic pharmaceutical production, and help mitigate input cost pressures.
Source: short-url.cc/1ymfK

3. India’s Central Consumer Protection Authority (CCPA) has imposed a ₹1 lakh penalty on a major beverages manufacturer for making a misleading “100% tender coconut water” claim. The authority held that the product’s labelling and advertising had the potential to mislead consumers regarding its composition, constituting a misleading advertisement and unfair trade practices under the consumer protection Act, 2019. The authority directed the company to discontinue the impugned advertisements and imposed a monetary penalty.
Source: short-url.cc/1sR6o

4. The Indian Multi-Disciplinary Committee of experts advised the National Pharmaceutical Pricing Authority to fix ceiling prices for intravenous fluids with advanced safety packaging at fifteen percent above existing regulated prices. If accepted, the proposal would encourage adoption of safer packaging technologies while ensuring these essential medicines remain subject to price regulation.
Source: short-url.cc/1sR6v

5. The Central Pollution Control Board (CPCB) has issued a notice directing registered battery waste recyclers to upload GST e-invoices for the sale of recovered key battery metals and metal compounds on the Battery Waste EPR Portal for EPR Certificate generation. EPR Certificates generated on the basis of non-GST e-invoices after 30 June 2026 will not be considered valid and may constitute non-compliance under the Battery Waste Management Rules, 2022.
Source: short-url.cc/1ymg3

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. we hope you enjoy reading it.

1. The NPPA’s Multi-Disciplinary Committee (MDC) flagged a typographical error in major pharmaceutical drug manufacturing company’s IPDMS Form I, reporting retail price of tablet as ₹13 per tablet instead of ₹91, leading to incorrect pricing. MDC has cautioned the manufacturer to avoid such negligence to prevent procedural delays.
Source: short-link.me/1aSCE

2. The Indian government has reportedly clarified that there is no official classification of drugs as “life-saving drugs.” However, to ensure affordability and accessibility, 930 formulations listed in the National List of Essential Medicines (NLEM) are under price control, leading to significant price reductions and improved patient access.
Source: short-link.me/16tjO

3. The Chhattisgarh High Court, in a recent interim order, has permitted Bachelor of Pharmacy (B.Pharm) graduates to apply for Pharmacist (Grade-II) posts under the National Health Mission (NHM). The court deemed the NHM’s exclusion of degree holders as arbitrary, a violation of Articles 14 and 16 of the Constitution.
Source: short-link.me/1aSCL

4. Indian pharmaceutical exports specifically generics and biosimilars -are currently exempt from the U.S. tariffs, underscoring their indispensable role in ensuring affordable, high-quality medicines for U.S. consumers. With about 40% of generics and 15% of biosimilars in the U.S. supplied by India, Pharmexcil has reportedly urged sustained collaboration to preserve stable, resilient pharmaceutical supply chains.
Source: short-link.me/1aSCW

5. United States Food and Drug Administration experts recommended dropping the “black box” warning on estrogen-based menopause therapies, especially low dose vaginal estrogen arguing the label has deterred women from effective treatment. They cited updated evidence showing benefits in reducing heart attack and bone fracture risk. In India, doctors are optimistic this move will boost confidence in hormone therapy, which remains underused despite its potential benefits for millions of postmenopausal women.
Source: short-link.me/1aSCZ